4.8 Editorial Material

Receptor tyrosine kinases in cancer escape from BRAF inhibitors

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib

Jeffrey A. Sosman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Editorial Material Pharmacology & Pharmacy

Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas

Roger S. Lo

PHARMACOGENOMICS (2012)

Article Oncology

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

Nikhil Wagle et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Article Multidisciplinary Sciences

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

Poulikos I. Poulikakos et al.

NATURE (2011)

Article Multidisciplinary Sciences

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Cory M. Johannessen et al.

NATURE (2010)

Article Multidisciplinary Sciences

Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation

Ramin Nazarian et al.

NATURE (2010)